Fortune 500 health care firms lead the way, ringing up double-digit sales growth over the past 12 months.
We don’t have enough data to say whether Obamacare is good for the country, but one thing is certain so far: It’s been a boon for the health care industry. In 2014 companies have mostly benefited from the law, which brought new customers to insurers, new paying patients to hospitals, and new prescription users to the pharmaceutical industry. The ongoing wave of M&A activity and successful drug debuts were also key factors driving the leading sector’s sales growth. (Click to enlarge chart.)
This story is from the January 2015 issue of Fortune.